---

(Fierce) - Just as Active Biotech's big pharma partner Teva ($TEVA) enrolled the first person in its high-stakes gamble on the third big Phase III study for the oral MS drug laquinimod, the Swedish biotech company announced that it had raked in $43 million from a wealthy family. Active says it will use the money to shore up its finances as it prepares for the next step in its evolution.